Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Jan 17, 2023

Keywords

ClinConnect Summary

The HORUS study, which stands for "Casting Light on Host-cytomegalovirus Interaction in Solid Organ Transplantation," is a research project aimed at understanding how the cytomegalovirus (CMV) affects patients who have received organ transplants. CMV infections are common after transplants and can lead to serious health issues, so this study seeks to learn more about how the virus interacts with the body, especially in patients who are taking medications to suppress their immune system. Researchers from seven European countries are working together to build a group of patients who have had organ transplants, collect important health information, and study how the body responds to CMV.

To participate in this study, individuals must be at least 18 years old and have received a kidney, lung, liver, or heart transplant. They need to provide written consent and be covered by health insurance. Participants will be closely monitored, and their health data will be collected to help researchers gain insights into CMV infections and improve care for future transplant patients. If you or a loved one is considering joining, it’s a chance to contribute to important research that could benefit many others in the transplant community.

Gender

ALL

Eligibility criteria

• A cohort 1 of solid-organ transplant recipients at day 0 of transplantation will be included:
• * Consecutive patients meeting the following inclusion criteria will be included:
• • Men and women,
• • Age \>= 18 years receiving a (living or deceased donor) kidney, lung, liver, and heart allograft,
• • written informed consent obtained from subject,
• • ability to understand and give their written consent,
• • affiliated to health insurance.
• * Exclusion criteria would be:
• • D-R- recipients,
• • participant unable or unwilling to comply with study procedures,
• • subjects who are legally detained in an official institution.
• A cohort 2 of solid-organ transplant recipients at day 0 of infection:
• * Consecutive patients meeting the following inclusion criteria will be included:
• • Men and women,
• • Age \>= 18 years receiving a (living or deceased donor) kidney, lung, liver, and heart allograft
• • written informed consent obtained from subject,
• • ability to understand and give their written consent,
• • affiliated to health insurance,
• • post-transplant CMV infection episode.
• * Exclusion criteria would be:
• • D-R- recipients,
• • participant unable or unwilling to comply with study procedures,
• • subjects who are legally detained in an official institution.